Although the risk remains relatively low for most patients, understanding the condition is essential for both healthcare providers and dental professionals to ensure appropriate prevention, early detection, and patient-centered management.
In this insightful discussion, Prof. Emma Clark and Dr. Lorna Hollingsworth explore the relationship between osteoporosis medications and osteonecrosis of the jaw, providing a comprehensive overview of the latest evidence surrounding this important topic.
Through a multidisciplinary perspective, the speakers address common concerns raised by patients and clinicians while clarifying misconceptions regarding medication-related risks and dental treatment.
Throughout the conversation, key subjects are discussed, including the mechanisms involved in ONJ development, risk factors, patient assessment, preventive dental strategies, and the importance of communication between dental and medical teams.
The speakers also examine current recommendations for maintaining oral health before, during, and after treatment with osteoporosis medications, helping clinicians make informed decisions that balance skeletal health and oral care.
In addition, the discussion highlights the critical role of patient education and interdisciplinary collaboration in reducing complications and supporting safe, effective treatment outcomes.
Practical insights are provided for managing patients who require dental procedures while receiving antiresorptive therapy.
This educational content is especially valuable for dentists, oral surgeons, periodontists, physicians, healthcare professionals, and students interested in expanding their understanding of medication-related osteonecrosis of the jaw and its implications for modern patient care.
👉 We invite you to watch the full discussion shared in this post and gain valuable insights from Prof. Emma Clark and Dr. Lorna Hollingsworth on Osteonecrosis of the Jaw (ONJ), osteoporosis medications, and the essential role of dental care in prevention and management.
